

Gastroenterology

www.gastrojournal.org

Vol. 151, No. 1

July 2016

TABLE OF
CONTENTS

Contents

ON THE COVER

Gastroenterology



Please see commentary by Graham and Laine on page 9 and Consensus Statement by Fallon, et al, on page 51 for more information. Thank you to Giovanni Suarez, PhD for providing the image.

COVERING THE COVER

- 1 A. T. Chan and C. S. Williams

COMMENTARIES

- 4 The Dawning of a New Editorial Board for *Gastroenterology*
D. A. Corley and R. M. Peek Jr

- 9 The Toronto *Helicobacter pylori* Consensus in Context
D. Y. Graham and L. Laine

- 13 Good News–Bad News: Current Status of GI Cancers
G. J. Gores and D. Lieberman

MEETING SUMMARY

- e1 2015 James W. Freston Single Topic Conference: A Renaissance in the Understanding and Management of Irritable Bowel Syndrome
L. Chang, M. M. Heitkemper, J. W. Wiley, and M. Camilleri

Video Related article in CGH

CME quiz Editorial accompanies this article Additional online content available Cover

Publisher: *Gastroenterology* (ISSN 0016-5085) is published monthly (semi monthly in May and June) in two indexed volumes by Elsevier Inc, 360 Park Avenue South, New York, NY 10010-1710. Periodicals postage paid at New York, NY and additional mailing offices. POSTMASTER: Send address changes to GASTROENTEROLOGY, Elsevier Health Sciences Division, Subscription Customer Service, 3251 Riverport Lane, Maryland Heights, MO 63043. 2016 US subscription rates: Individual, \$658.00; student and resident, \$251.00. Outside of the U.S. and possessions: Individual, \$968.00; student and resident, \$562.00; surface delivery, no additional charge; air mail delivery, add \$78.00. Prices subject to change without notice.

MENTORING, EDUCATION, AND TRAINING CORNER

- 17 **How to Select a Mentor as a Trainee and Junior Faculty**
D. Lieberman

EDITORIALS

- 20 **Toward a Better Drug for Gastroparesis: The Problem With a Moving Target**
P. J. Pasricha and W. Snape
See Lembo A et al on page 87.
- 22 **First Do No Harm: Is It Safe to Use Immunosuppressants in Inflammatory Bowel Disease Patients With Prior Cancer?**
G. C. Nguyen
See Shelton E et al page 97
- 25 **Detectable Drug Levels in Infants Exposed to Biologics: So What?**
P. Kathpalia, S. Kane, and U. Mahadevan
See Julsgaard M et al on page 110.
- 27 **Are Facultative Reserve ISC's the Cellular Origin of Familial Small Intestinal Neuroendocrine Tumors?**
P. J. Dempsey
See Sei Y et al on page 140.

GASTROENTEROLOGY IN MOTION

- 30 **Endoscopic Ultrasound-Guided Transesophageal Drainage of an Infected Aneurysm After Aortic Stent Graft Placement**
E. Rodrigues-Pinto and T. H. Baron

CLINICAL CHALLENGES AND IMAGES IN GI

- 32 **Unexpected Steatotic Liver Lesions**
C. De Vito, L. Rubbia-Brandt, and C. Toso
- 34 **Rare, Life-Threatening Duodenal Bleeding**
E. Avivi, G. Hermann, and H. Shirin
- 37 **Hepatitis C and Numerous Disappearing Hepatic Nodules: No-dule C It, No-dule Don't**
M. J. Klinge, A. A. Borhani, and S. M. Malik
- 40 **An Unusual Cause of Massive Ascites**
U. Fuchizaki, K. Yamada, and S. Matsuda

ELECTRONIC CLINICAL CHALLENGES AND IMAGES IN GI

For a full list, please see the table of contents online at www.gastrojournal.org.

PRACTICAL TEACHING CASE

- 43 **Young Adult With Multivisceral Lesions and Hypoglycemia**
N. Vashistha, B. Aggarwal, and D. Singhal

AGA CLINICAL PRACTICE UPDATES

- 45 **Introduction to Clinical Practice Update Committee Articles**
D. A. Katzka, L. S. Friedman, J. M. Inadomi, A. M. Kalloo, L. S. Kim, J. Koch, D. Lieberman,
G. R. Lichtenstein, J. K. Lim, J. E. Pandolfino, A. S. Shin, and M. R. Siedler

AGA CLINICAL PRACTICE UPDATE: COMMENTARY

- 46 **Infection Using ERCP Endoscopes**
B. T. Petersen, J. Koch, and G. G. Ginsberg

CONSENSUS STATEMENT

- 51 **The Toronto Consensus for the Treatment of *Helicobacter pylori* Infection in Adults**
C. A. Fallone, N. Chiba, S. V. van Zanten, L. Fischbach, J. P. Gisbert, R. H. Hunt, N. L. Jones, C. Render,
G. I. Leontiadis, P. Moayyedi, and J. K. Marshall

REVIEWS AND PERSPECTIVES

Reviews in Basic and Clinical Gastroenterology and Hepatology

- 70 **Hepatitis C Virus Resistance to Direct-Acting Antiviral Drugs in Interferon-Free Regimens**
J.-M. Pawlotsky

ORIGINAL RESEARCH

Full Reports

Clinical—Alimentary Tract

- 87 **Relamorelin Reduces Vomiting Frequency and Severity and Accelerates Gastric Emptying in Adults With Diabetic Gastroparesis**
A. Lembo, M. Camilleri, R. McCallum, R. Sastre, C. Breton, S. Spence, J. White, M. Currie,
K. Gottesdiener, and E. Stoner, for the RM-131-004 Trial Group

See editorial on page 20.

In patients with gastrointestinal complications of diabetes, the experimental medication Relamorelin may improve gastrointestinal symptoms such as vomiting, and improve delayed stomach emptying.

- 97 **Cancer Recurrence Following Immune-Suppressive Therapies in Patients With Immune-Mediated Diseases: A Systematic Review and Meta-analysis**
E. Shelton, D. Laharie, F. I. Scott, R. Mamtani, J. D. Lewis, J.-F. Colombel,
and A. N. Ananthakrishnan

See editorial on page 22.

Commonly used immunosuppressives for inflammatory bowel disease and other auto-immune diseases did not increase the risk of cancer recurrence after a cancer diagnosis.

110

E

Concentrations of Adalimumab and Infliximab in Mothers and Newborns, and Effects on Infection

M. Julsgaard, L. A. Christensen, P. R. Gibson, R. B. Geary, J. Fallingborg, C. L. Hvas, B. M. Bibby, N. Uldbjerg, W. R. Connell, O. Rosella, A. Grosen, S. J. Brown, J. Kjeldsen, S. Wildt, L. Svenningsen, M. P. Sparrow, A. Walsh, S. J. Connor, G. Radford-Smith, I. C. Lawrance, J. M. Andrews, K. Ellard, and S. J. Bell

See editorial on page 25.

Infants exposed to anti-TNF agents during pregnancy had normal outcomes without increased infection, unless they were also receiving thiopurines. Slow drug clearance suggests young infants may be at risk from live vaccines.

120

WWW

Administration of Antibiotics to Children Before Age 2 Years Increases Risk for Childhood Obesity

F. I. Scott, D. B. Horton, R. Mamtani, K. Haynes, D. S. Goldberg, D. Y. Lee, and J. D. Lewis

Antibiotic exposure before 2 years of age is associated with subsequent development of early-onset obesity after adjusting for multiple risk factors, including maternal or sibling obesity

Clinical—Liver

130

WWW

Effects of Eradicating Hepatitis C Virus Infection in Patients With Cirrhosis Differ With Stage of Portal Hypertension

V. Di Marco, V. Calvaruso, D. Ferraro, M. G. Bavetta, G. Cabibbo, E. Conte, C. Cammà, S. Grimaudo, R. M. Pipitone, F. Simone, S. Peralta, A. Arini, and A. Craxi

In patients with HCV and compensated cirrhosis, HCV eradication reduced the risk for liver decompensation, liver cancer, and death, even in patients with evidence of advanced liver disease, such as esophageal varices.

Basic and Translational—Alimentary Tract

140

E WWW

Polyclonal Crypt Genesis and Development of Familial Small Intestinal Neuroendocrine Tumors

Y. Sei, J. Feng, X. Zhao, J. Forbes, D. Tang, K. Nagashima, J. Hanson, M. M. Quezado, M. S. Hughes, and S. A. Wank

See editorial on page 27.

Familial small intestinal serotonin-producing carcinoid tumors are multifocal and polyclonal in origin; arising from a subset of enterochromaffin cells at the crypt base that undergo bottom-up morphogenesis and spread by budding.

152

WWW

Defective Intestinal Mucin-Type O-Glycosylation Causes Spontaneous Colitis-Associated Cancer in Mice

K. Bergstrom, X. Liu, Y. Zhao, N. Gao, Q. Wu, K. Song, Y. Cui, Y. Li, J. M. McDaniel, S. McGee, W. Chen, M. M. Huycke, C. W. Houchen, L. A. Zenewicz, C. M. West, H. Chen, J. Braun, J. Fu, and L. Xia

Impaired expression of certain carbohydrates (O-glycans) renders the colonic mucus barrier more susceptible to microbial-induced inflammation and inflammation-related cancers.

Basic and Translational—Pancreas

165

WWW

Glucose-Dependent Insulinotropic Peptide Stimulates Glucagon-Like Peptide 1 Production by Pancreatic Islets via Interleukin 6, Produced by α Cells

K. Timper, E. Dalmas, E. Dror, S. Rützi, C. Thienel, N. S. Sauter, K. Bouzakri, B. Bédard, F. Pattou, J. Kerr-Conte, M. Böni-Schnetzler, and M. Y. Donath

The insulin-regulating protein GIP stimulates production of compounds that modify inflammation and promote insulin secretion; these represent potential targets for therapy.

- 180** **Loss of P53 Function Activates JAK2-STAT3 Signaling to Promote Pancreatic Tumor Growth, Stroma Modification, and Gemcitabine Resistance in Mice and Is Associated With Patient Survival**
S. M. Wörmann, L. Song, J. Ai, K. N. Diakopoulos, M. U. Kurkowski, K. Görgülü, D. Ruess, A. Campbell, C. Doglioni, D. Jodrell, A. Neesse, I. E. Demir, A.-P. Karpathaki, M. Barenboim, T. Hagemann, S. Rose-John, O. Sansom, R. M. Schmid, M. P. Protti, M. Lesina, and H. Algül

Loss of tumor suppressor protein P53 function in pancreatic cancer was associated with alterations in cancer cell signaling, tumor growth, and resistance to the chemotherapy drug gemcitabine.

CONTINUING MEDICAL EDUCATION (CME)/MOC ACTIVITIES

- e22 Exam 1: Endoscopic Ultrasound-Guided Transesophageal Drainage of an Infected Aneurysm After Aortic Stent Graft Placement**
- e24 Exam 2: Young Adult With Multivisceral Lesions and Hypoglycemia**
- e25 Exam 3: The Toronto Consensus for the Treatment of *Helicobacter pylori* Infection in Adults**
- e27 Exam 4: Cancer Recurrence Following Immune-Suppressive Therapies in Patients With Immune-Mediated Diseases: A Systematic Review and Meta-analysis**

AGA SECTION

- 194 Abstracts From the "Advancing Clinical Practice: GI Fellow-Directed Quality Improvement Projects" Session at DDW 2016**

SELECTED SUMMARIES

- 206 Probiotic Gut Bacteria Enhance Cancer Immunotherapy in a Mouse Model of Melanoma**
N. Dey and M. A. Ciorba
- 207 Surveillance of Asymptomatic Pancreatic Cysts – How Long is Long Enough?**
S. Amin, C. J. DiMaio, and M. K. Kim

CORRESPONDENCE

- 210 Roux-en-Y Gastric Bypass and Intestinal Glucose Handling: A Salty Sweet Operation**
F. Pattou, M. Daoudi, and G. Baud
- 211 Reply**
M. Le Gall, A. Bado, and J.-B. Cavin
- 211 The METEOR Trial: The Burial of Methotrexate in Ulcerative Colitis?**
F. S. Macaluso, S. Renna, M. Cottone, and A. Orlando

- 212 **Reply**
F. Carbonnel, D. Laharie, and J. F. Colombel
- 213 **Integrin $\alpha E\beta 7$ in Inflammatory Bowel Disease: Friend or Foe?**
C. Smids, C. S. Horjus-Talabur Horje, and E. G. van Lochem
- 214 **Reply**
M. E. Keir, G. W. Tew, and J. A. Hackney

Access to the full content of *Gastroenterology Online* is available to all subscribers!

AGA members have seamless access to full *Gastroenterology* content from the AGA Web site. Simply sign in to <http://www.gastro.org>, visit the Publications section of the Web site, and click on *Gastroenterology*. You will be directed to the Journal Web site and will have full access to all content without having to supply a different username and password. Members can also visit <http://www.gastrojournal.org> directly and click on "Activate Online Access." Nonmember subscribers must create an online user account and activate their subscription to access the full text of articles on *Gastroenterology Online*. To activate your individual online subscription, please visit <http://www.gastrojournal.org> and click on "Activate Online Access." To activate your account, you

will need your subscriber account or member number, which you can find on your mailing label, (AGA members must use their 10-digit member number, including leading zeros). If you have any questions regarding your online subscription please call Elsevier Customer Service at (800) 654-2452.

Institutional access to *Gastroenterology Online* will be allowed only by limited site licensing. Further instructions will be available online. Personal subscriptions to *Gastroenterology Online* are for individual use only and may not be transferred. Use of *Gastroenterology Online* is subject to agreement to the terms and conditions of use as indicated online.

AGA Member Number

Your Account Number

**Sample
mailing
label**

GAST0000101864
JANE DOE
531 MAIN ST
CENTER CITY, NY 10001-001

1GAST V91-4 1234567-8
JANE DOE
531 MAIN ST
CENTER CITY, NY 10001-001